Inventor · disambiguated record
Stephan Klinz
Also filed as: KLINZ STEPHAN · KLINZ STEPHAN G
2 granted patents·12 pending applications·2 citations·filing 2006–2023
45Inventor score
Files withMERRIMACK PHARMACEUTICALS INC7FUSION PHARMACEUTICALS INC2IPSEN BIOPHARM LTD2MERCK PATENT GMBH2MERRIRNACK PHARMACEUTICALS INC1
Top patents by PatentIndex Score
14 records- 0170US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 0263US2020360367A1Treatment of Breast Cancer with Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2019·Application pending·0 cites
- 0359US2019142822A1Treatment of Breast Cancer with Liposomal IrinotecanIPSEN BIOPHARM LTD·Filed 2018·Application pending·0 cites
- 0457US2010330029A1Cancer Treatments with Radiation and ImmunocytokinesMERCK PATENT GMBH·Filed 2009·Application pending·0 cites
- 0555US2024207455A1Combination comprising a neurotensin receptor binding compound and napoxFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0655US2024216550A1Combination comprising a neurotensin receptor binding compound and napoliFUSION PHARMACEUTICALS INC·Filed 2023·Application pending·0 cites
- 0755US2014170075A1Non-invasive imaging methods for patient selection for treatment with nanoparticulate therapeutic agentsMERRIRNACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0853US2017340656A1Non-Invasive Imaging Methods for Patient Selection for Treatment with Nanoparticulate Therapeutic AgentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 0952US2007104689A1Compositions and methods for treating tumors presenting survivin antigensMERCK PATENT GMBH·Filed 2006·Application pending·0 cites
- 1052US2017151226A1Treatment of Breast Cancer with Liposomal IrinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1150US9610249B2Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Apr 4, 2017·0 cites·22 claims
- 1249US2017189335A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1345US2016038416A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1440US2016346272A1Treatment of breast cancer with liposomal irinotecanMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Stephan Klinz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →